BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla’s two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb’s anti-PD-1 therapy nivolumab.
[BioAtla, Inc. (PR Newswire, Inc.)]
7992332
{7992332:BBBBBBBB}
apa
50
1
170517
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
